Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Related Content:

University of Chicago Medicine Comprehensive Cancer CenterOncLive TVImmunotherapy in MelanomaMelanoma & Skin CancerImmuno-Oncology
Revisit Every OncLive On Air Episode From June 2024
Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer
Dr Gong on the Frontline Use of PARP Inhibitors in mCRPC